In a strategic move that will indubitably send ripples through the biologics sector, Zydus Lifesciences has acquired two sophisticated biologics manufacturing facilities in the heart of California’s biotech hub, from renowned immuno-oncology company Agenus Inc. This acquisition marks a significant step forward for Zydus, positioning the company to not just dip its toes, but dive […]
Tag: Biologics Manufacturing
Agenus, Zydus Lifesciences Collaborate to Advance Biologics Manufacturing
Agenus and Zydus Lifesciences have entered a $141M strategic collaboration to advance their BOT/BAL programs and expand Zydus’ biologics manufacturing in the US. Forward-looking statements in this press release highlight the companies’ botensilimab and balstilimab programs, expected regulatory timelines, and filings. It is crucial to note that these statements are subject to risks and uncertainties […]
Zydus Strengthens Biologics Presence Through Agenus Deal
Zydus has solidified its position in the global biologics market through the acquisition of Agenus, which includes biologics manufacturing sites in Emeryville and Berkeley, California. The deal involves an upfront payment of $75 million, with an additional $50 million in milestone-based payments over three years. These facilities will support Zydus’ new biologics CDMO business, catering […]
